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still present for the patients that were under therapy after 42 months.
All scores obtained at followup visits showed statistical signiﬁcance
(p< 0.001) when compared with scores obtained at baseline.
Conclusions: Our data suggest that hip viscosupplementation may be
an effective and cost-saving treatment for both patients and Healthcare
system, not only because the spending for NSAID is lowered (direct
costs), but also because gastrointestinal and cardiovascular side effects
commonly associated with NSAID may be reduced (indirect costs).
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Purpose: In search for potential new therapies in the treatment of
osteoarthritis (OA), attention has focused also on tetracyclines and their
ability to slow down the progression of OA. Several possible mechanisms
have been proposed, including inhibition of the activity and expression
of inducible nitric oxide synthase (iNOS) and matrix metalloproteinases
(MMPs). Using normal bovine articular cartilage, minocycline were found
to have a stronger inhibitory effect on e.g. the expression of iNOS and
MMP-1 than doxycycline.
In this line, the purpose of this in vitro study was to determine system-
atically whether tetracyclines (1) inﬂuences the synthesis and release of
PGs, MMPs and PGE2 also from human OA cartilage, (2) are affected by
the degree of OA alterations, (3) are different with respect to their individ-
ual ability to modulate cartilage metabolism, and (4) affect chondrocyte
viability within human OA cartilage explants.
Methods: Full-thickness cartilage explants of the lateral compartment of
the femoral condyles were taken from OA patients undergoing knee re-
placement surgery. 4-mm-diameter articular cartilage discs were obtained
using a biopsy punch. The degree of OA changes of the femoral condyles
was determined according to Collins. Explants from mild (Collins grade
0−1.5) or moderately (Collins grade >1.5−3) affected human OA condyles
were cultured separately in supplemented Ham’s F12 media with media
changes every 3−4 days. Explants were treated with 1, 10, 50 or 100 mM
minocycline, doxycycline or tetracycline in the presence or absence of rec.
human Il-1b (5 ng/ml). PG synthesis was determined by the incorporation
of 35SO4 during the ﬁnal 18 h of the 11 days experiments whereas the
content of PGs were quantitated with the DMMB-assay. The viability of
chondrocytes was assessed microscopically using ﬂuorescein diacetate
and propidium iodide. Nitrite levels in media were measured by using the
Griess reaction. MMP-1, -8, and -13 as well as PGE2 were determined
in media with ELISAs. Results were compared to untreated explants
removed from the same joint. Each experimental condition was repeated
ﬁve times using explants always obtained from 6 different patients (N=6).
Results: The degree of OA alterations of explants can have a profound
modulatory effect on the inﬂuence of tetracylines on cartilage metabolism.
Furthermore, doxycycline partly displayed a weaker pharmacological
effect than minocycline, whereas tetracycline was found to have the
lowest potential to change cartilage metabolism. The viability of explants
was not affected by any of the drugs tested.
Conclusions: Our study indicate that the pharmacological efﬁcacy of
tetracyclines can be dependent on the clinical stage of OA. In addition,
our ﬁndings indicate that minocycline possess a stronger potential than
doxycycline to slow down cartilage destruction during OA.
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Purpose: To investigate the efﬁcacy of the anabolic agent ﬁbroblast
growth factor 18 (rhFGF18; AS902330) in counteracting structural dam-
age and functional impairment in a dog anterior cruciate ligament (ACL)
model of osteoarthritis (OA) over 26 weeks.
Methods: From week 4 after surgical section of the right ACL in mongrel
dogs, intra-articular injections of AS902330 3mg, 10mg or 30mg per joint
(n = 8/dose group) or placebo (saline; n = 8) were given into the OA knee
once a week for 3 consecutive weeks. The animals were followed up
through week 26. Peak vertical force (PVF) was recorded at baseline
and at weeks 4, 8, 14, 20 and 26. MRI of the stiﬂe joint was performed
at weeks 4, 8 and 26. Semi-quantitative scores were determined for
osteophytosis, bone marrow lesions and cartilage defects, and cartilage
volume was measured. Macroscopic measurements of cartilage lesions
(condyles and plateaus) were performed at weeks 8 (3 dogs/group) and
26 (5 dogs/group). Exposure was determined using high performance
ELISA. All injections were undertaken and evaluations performed by
investigators blinded to the assigned treatment.
Results: Following section of the ACL, all dogs developed functional
impairment, but there was less loss of PVF in dogs treated with any of
the tested doses of AS902330 than in controls. In placebo-treated dogs,
the evolution of structural damage over time (weeks 4−26) correlated
with worsening limb function as expressed by PVF. As early as week 8
(i.e. at the end of intra-articular therapy), differences in joint functionality
could be detected between AS902330-treated dogs and placebo-treated
dogs. At week 8, mean PVF loss in the AS902330-treated group given
30mg/joint was 36.3% of baseline values, versus 47.8% in controls
(p =0.082; Mann-Whitney U test). A signiﬁcant difference in PVF loss
was also seen between AS902330 30mg and saline at week 14 (26.2%
vs 44.4%, p =0.007). The difference between groups (AS902330 30 mg
vs saline) was less pronounced at weeks 20 and 26 (35.2% vs 38.5%;
23.9% vs 33.5%, respectively). Measures of contact area followed a
similar pattern to PVF. Macroscopic gross pathology and microscopic
evaluation of cartilage using the International Cartilage Repair Society
scoring system revealed a clear reduction in the severity of cartilage
lesions in AS902330-treated dogs compared with controls at the end of
therapy (8 weeks) and after longer term follow-up (26 weeks). In addi-
tion, immunostaining for catabolic factors (e.g. matrix metalloproteinases,
inducible nitric oxide synthase) revealed a reduction in staining in the
cartilage of AS902330-treated dogs, which was maintained up to the end
of the study period (26 weeks). Systemic exposure after intra-articular
administration of AS902330 was below the lower limit of quantiﬁcation
(50 pg/mL).
Conclusions: Intra-articular injection with the anabolic agent AS902330
was shown to reduce progression of structural damage and alleviate limb
impairment in an ACL model of OA in dogs. The reduction in catabolic
parameters in the OA joint of treated animals, improved histopathology
scoring, and the improved functionality compared with saline-treated con-
trols support the hypothesis that treatment with rhFGF18 may inﬂuence
the course of OA and reduce functional impairment.
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Purpose: Osteoarthritis (OA) and rheumatoid arthritis are characterized
by a reduction of extracellular matrix and increased catabolism of colla-
gen ﬁbers and glycosaminoglycans in joints. Conventional therapy with
traditional non steroidal anti-inﬂammatory drugs (NSAIDs) and selective
COX-2 inhibitors may increase progression of cartilage degradation,
especially in long-term treatments (Mastbergen, Arthritis Res Ther 2006).
The role of nitric oxide (NO) in OA is still controversial, since it has
been recognized as a marker of inﬂammation and a possible cause
of chondrocyte loss, but also as a potent immuno-modulating factor
improving joint vascular perfusion (Hancock & Riegger-Krugh, Clin J Pain
